Semaglutide promotes bone marrow–derived progenitor cell flux towards an anti-inflammatory and pro-regenerative profile in high-risk patients: the SEMA-VR CardioLink-15 trial
Brady Park(St. Michael's Hospital), Subodh Verma(St. Michael's Hospital), Hwee Teoh(St. Michael's Hospital), Ehab Bakbak(The University of Queensland), Aishwarya Krishnaraj(St. Michael's Hospital), Bhavaani Lambotharan(Legacy International), David A. Hess(Western University), Adrian Quan(St. Michael's Hospital), Fallon Dennis(St. Michael's Hospital), Yi Pan(Liaoning Shihua University), Vaasudevan Lambotharan(Health Education North West), Aruna Lambotharan(Legacy International), Elizabeth Misner(St. Michael's Hospital), Arianna Z He(St. Michael's Hospital), Veena Thayanithy(North York General Hospital), C. David Mazer(St. Michael's Hospital)
Cited by 8
Related Papers
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
|New England Journal of Medicine|2019|6.8k
Empagliflozin in Heart Failure with a Preserved Ejection Fraction
|New England Journal of Medicine|2021|4.6k
New Markers of Inflammation and Endothelial Cell Activation
|Circulation|2003|733
Left Atrial Appendage Occlusion during Cardiac Surgery to Prevent Stroke
|New England Journal of Medicine|2021|711
Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction
|New England Journal of Medicine|2024|693